Guest: Andrew Blauvelt, MD, MBA



As the only FDA-designated selective TYK2 inhibitor, deucravacitinib has emerged as a potential therapeutic option for scalp psoriasis. And after analyzing its impacts in a phase III clinical trial, it has continued to show promise in terms of both efficacy and safety. Hear more about deucravacitinib and how it compares to alternate options like JAK inhibitors from Dr. Andrew Blauvelt, a dermatologist and clinical researcher with a focus on innovative treatments for psoriasis.

Ver todos los episodios